Avalo Therapeutics, Inc.

Avalo Therapeutics, Inc. - PE Ratioverified

AVTX

Price:

$14.7

Market Cap:

$166.02M

Avalo Therapeutics, Inc. is a precision medicine company in the clinical development phase, dedicated to identifying, advancing, and marketing specialized treatments for patients experiencing critical unmet medical needs across the fields of immunology, immuno-oncology, and rare genetic disorders. Among its key pipeline assets is AVTX-002, a fully human monoclonal antibody designed to inhibit LIGHT. This drug is currently undergoing Phase II clinical trials for non-eosinophilic asthma and inflammatory bowel diseases, specifically moderate to severe Crohn's disease and ulcerative colitis. Furthermore, AVTX-002 is also being investigated in Phase III for its potential to treat acute respirator...[Read more]

Industry

Biotechnology

IPO Date

2015-10-14

Stock Exchange

NASDAQ

Ticker

AVTX

The PE Ratio as of June 2026 (TTM) for Avalo Therapeutics, Inc. (AVTX) is -2.64

According to Avalo Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -2.64. This represents a change of -12.32% compared to the average of -3.01 of the last 4 quarters.

Avalo Therapeutics, Inc. (AVTX) Historical PE Ratio (quarterly & annually)

How has AVTX PE Ratio performed in the past?

The mean historical PE Ratio of Avalo Therapeutics, Inc. over the last ten years is -14.35. The current -2.64 PE Ratio has changed 1.74% with respect to the historical average. Over the past ten years (40 quarters), AVTX's PE Ratio was at its highest in in the December 2019 quarter at 48.58. The PE Ratio was at its lowest in in the December 2017 quarter at -414.39.

Quarterly (TTM)
Annual

Average

-14.35

Median

-2.45

Minimum

-115.57

Maximum

4.96

Avalo Therapeutics, Inc. (AVTX) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Avalo Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 2.05%

Maximum Annual PE Ratio = 4.96

Minimum Annual Increase = -156.50%

Minimum Annual PE Ratio = -115.57

Quarterly (TTM)
Annual
YearPE RatioChange
2025-3.1180.80%
2024-1.722.05%
2023-0.08-92.96%
2022-1.14-45.81%
2021-2.10-30.27%
2020-3.01-84.09%
2019-18.94575.29%
2018-2.80-156.50%
20174.96-104.29%
2016-115.57-80.58%

Avalo Therapeutics, Inc. (AVTX) Average PE Ratio

How has AVTX PE Ratio performed in the past?

The current PE Ratio of Avalo Therapeutics, Inc. (AVTX) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages

3-year avg

-1.64

5-year avg

-1.63

10-year avg

-14.35

Avalo Therapeutics, Inc. (AVTX) PE Ratio vs. Peers

How is AVTX’s PE Ratio compared to its peers?

Avalo Therapeutics, Inc.’s PE Ratio is greater than Prelude Therapeutics Incorporated (-4.08), less than Inventiva S.A. (-1.61), greater than Eupraxia Pharmaceuticals Inc. (-6.09), less than Caribou Biosciences, Inc. (-1.15), less than Coherus Oncology, Inc. (-1.16), greater than Orchestra BioMed Holdings, Inc. (-2.81), less than Aardvark Therapeutics, Inc. Common Stock (-1.22), less than Tenaya Therapeutics, Inc. (-1.55), greater than Enanta Pharmaceuticals, Inc. (-4.62), less than Black Diamond Therapeutics, Inc. (-2.18),

Build a custom stock screener for Avalo Therapeutics, Inc. (AVTX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Avalo Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Avalo Therapeutics, Inc. (AVTX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Avalo Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Avalo Therapeutics, Inc.'s PE Ratio?

How is the PE Ratio calculated for Avalo Therapeutics, Inc. (AVTX)?

What is the highest PE Ratio for Avalo Therapeutics, Inc. (AVTX)?

What is the 3-year average PE Ratio for Avalo Therapeutics, Inc. (AVTX)?

What is the 5-year average PE Ratio for Avalo Therapeutics, Inc. (AVTX)?

How does the current PE Ratio for Avalo Therapeutics, Inc. (AVTX) compare to its historical average?